Gravitas Feeding Tube System for Nasogastric Tubes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the Gravitas Feeding Tube System to determine its effectiveness and safety for newborns in hospitals. The study focuses on infants in the NICU who require feeding tubes for nutrition, fluids, and medications. Infants in the NICU needing a nasogastric tube (a tube from the nose to the stomach) might be suitable candidates. The trial compares the new system with standard care to assess if it is better or safer. As an unphased trial, this study provides a unique opportunity to contribute to innovative healthcare solutions for newborns.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether participants need to stop taking their current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Gravitas Feeding Tube System is safe for NICU patients?
In a previous study, researchers tested the Gravitas Feeding Tube System in newborns and found it safe. They monitored key indicators, such as temperature and electrical conductivity (to ensure correct tube placement), during the procedure. No serious problems occurred with the system during these tests.
Another report showed that the Entarik Feeding Tube System, similar to the Gravitas system, was as safe and effective as other devices used for the same purpose. This suggests that the Gravitas Feeding Tube System should also be well-tolerated.
Overall, research indicates the system is safe for use in newborns, with no major issues noted in these studies.12345Why are researchers excited about this trial?
The Gravitas Feeding Tube System is unique because it offers a potentially more efficient and comfortable delivery method for nasogastric feeding compared to traditional tubes. Researchers are excited about this system because it may reduce patient discomfort and improve the ease of insertion and stability of the tube, which are common challenges with current nasogastric tube options. By focusing on these enhancements, the Gravitas system could lead to a better overall experience for patients needing nutritional support through nasogastric tubes.
What evidence suggests that the Gravitas Feeding Tube System is effective for NICU patients?
Research has shown that the Gravitas Feeding Tube System, which participants in this trial may receive, effectively delivers nutrition, fluids, and medications to newborns. Studies have found that it safely places the tube, reducing the risk of misplacement, which can occur in up to 59% of cases with other tubes. The system uses a special method to verify correct tube placement, ensuring real-time accuracy. Overall, the Gravitas Feeding Tube System appears to be a promising option for feeding and administering medicine to newborns.36789
Are You a Good Fit for This Trial?
This trial is for newborns in intensive care or on a medical floor who need a nasogastric (NG) tube sized 5-8 Fr for feeding. They should be between 0 to 18 weeks old, can be up to 12 weeks premature, and must require enteral feeding for over 6 hours. Both ventilated and non-ventilated neonates are eligible if they have consent from a legal representative.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Validation of the Gravitas Feeding Tube System Placement Algorithm and evaluation of the safety and effectiveness of the Gravitas Feeding Tube in neonates
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Gravitas Feeding Tube System
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gravitas Medical, Inc.
Lead Sponsor